Loading stock data…
WALD
$1.67-0.13 (-7.22%)
Pre-Market$1.66-0.01 (-0.60%)· Last close May 11
Waldencast plc operates in the beauty and wellness industry in the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Waldencast plc in the Consumer Defensive sector is trading at $1.67. The stock is currently 48% below its 52-week high of $3.22, remaining 2.3% below its 200-day moving average. Technical signals show overbought RSI of 73 and bullish MACD crossover, explaining why WALD maintains its current current market pressure. The Whystock Score of 0/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 73) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.67
Potential Upside
5%
Whystock Fair Value$1.75
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Waldencast plc operates in the beauty and wellness industry in the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand. The company operates through two segments, Obagi Medical and Milk Makeup. It offers skin care produc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$102.61M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.07
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
0.60%
Volume
Today's trading volume
396,515
Recent News
Spotlight On 3 Promising Penny Stocks With Market Caps Over $100M
Over the last 7 days, the United States market has risen 3.2%, with a notable climb of 31% over the past year and earnings forecasted to grow by 16% annually. In such a robust market environment, identifying stocks that combine solid financials with growth potential becomes crucial for investors. Penny stocks, although an outdated term, remain relevant as they often represent smaller or newer companies that can offer unique opportunities for significant returns when backed by strong...
How Waldencast (WALD) Story Is Shifting As Targets Fall And Brand Hopes Persist
The fair value estimate for Waldencast has been reset from US$3.08 to US$1.87 per share, putting the recent round of reduced price targets into clear focus. This shift sits alongside research that separates analysts into those concerned about near term execution and those still focused on the potential of Obagi, Milk, and upcoming product catalysts. As you read on, you will see how these changing targets fit into the broader narrative and what to watch as the story develops. Stay updated as...
Top Premarket Gainers
Waldencast (WALD) shares were up 31% in Wednesday premarket activity, a day after the company said t
Promising Penny Stocks To Consider In April 2026
The market has climbed 3.0% in the last 7 days and an impressive 26% over the past year, with earnings projected to grow by 16% annually in the coming years. For those looking to invest in smaller or newer companies, penny stocks — despite their somewhat outdated name — can still offer surprising value. These stocks often represent a mix of affordability and growth potential when backed by solid financials, and we will explore several that stand out for their financial strength.
Obagi Medical, It’s a Secret Med Spa collaborate for ALOHA program
Obagi Medical announced It’s a Secret Med Spa as a key partner in the Aesthetics Leadership with Obagi’s Hyaluronic Acid Program. It’s a Secret Med Spa will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple locations and structured evaluation programs.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with